Tag Archive for: heidelberg pharma

Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024

Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024. Read more…

Interim Management Statement on the First Three Months of 2024

First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the […]

Heidelberg Pharma to host R&D Webinar following novel data presented at AACR

Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media. The R&D webinar will feature presentations from Heidelberg Pharma’s management […]

Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101

Ladenburg, Germany, 27 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the […]

Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

First efficacy data from the clinical trial with HDP-101 in multiple myeloma Expansion of the ADC technology platform to include further payloads New Management Board team Successful financing activities; sales revenue and other income above plan Conference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT Ladenburg, Germany, 25 […]